Cargando…
Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan
For decades, psychostimulants have been the gold standard pharmaceutical treatment for attention-deficit/hyperactivity disorder (ADHD). In the United States, an astounding 9% of all boys and 4% of girls will be prescribed stimulant drugs at some point during their childhood. Recent meta-analyses hav...
Autores principales: | Dutta, Cintya Nirvana, Christov-Moore, Leonardo, Ombao, Hernando, Douglas, Pamela K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548548/ https://www.ncbi.nlm.nih.gov/pubmed/36226261 http://dx.doi.org/10.3389/fnhum.2022.938501 |
Ejemplares similares
-
Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan
por: Wang, Liang-Jen, et al.
Publicado: (2016) -
The Perception of Primary School Teachers Regarding the Pharmacotherapy of Attention Deficit Hyperactivity Disorder
por: Gregório, João, et al.
Publicado: (2021) -
Executive Functions in Neurodevelopmental Disorders: Comorbidity Overlaps Between Attention Deficit and Hyperactivity Disorder and Specific Learning Disorders
por: Crisci, Giulia, et al.
Publicado: (2021) -
Dose-Response Effects of Acute Aerobic Exercise Intensity on Inhibitory Control in Children With Attention Deficit/Hyperactivity Disorder
por: Tsai, Yu-Jung, et al.
Publicado: (2021) -
Shared genetic architecture between attention-deficit/hyperactivity disorder and lifespan
por: Vilar-Ribó, Laura, et al.
Publicado: (2023)